Dutch biopharmaceutical company Crucell expects its operating loss for 2010 to be in the €20-25 million range, citing costs associated with microbial contamination at its Shingal facility in Korea as a key factor.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Electroporation specialist Inovio Biomedical Corp and vaccine
developer VGX Pharmaceuticals believe that their recently announced
merger will create a firm capable of rapidly moving DNA vaccine
candidates from the laboratory to the...
NanoImaging Services has opened what it claims is a first of its
kind fee-for-service imaging business to enable structural
characterisation and validation of biological drugs throughout the
GlaxoSmithKline's cervical cancer vaccine, Cervarix, has received a
positive opinion from the European Commission for Human Medicinal
Products (CHMP), bringing a competitor to Merck & Co's dominant
Gardasil vaccine a...